Pegvisomant

Pegvisomant Uses, Dosage, Side Effects, Food Interaction and all others data.

Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.

Somavert is used for the treatment of acromegaly, which arises from excessive IGF-1 levels. Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and IGF binding protein-3 (IGFBP-3). This reduces the symptoms of acromegaly.

Table Of contents

• Pegvisomant
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Pegvisomant
Availability	Prescription only
Generic	Pegvisomant
Pegvisomant Other Names	Pegvisomant
Related Drugs	octreotide, bromocriptine, Sandostatin, lanreotide, Somatuline Depot, Parlodel
Weight	10mg, 15mg, 20mg, 25mg, 30mg,
Type	Subcutaneous Powder For Injection, Subcutaneous
Formula	C990H1532N262O300S7
Weight	22129.0 Da
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	United States
Last Updated:	September 19, 2023 at 7:00 am

Uses

Pegvisomant is a growth hormone receptor antagonist used to treat acromegaly.

Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.

Pegvisomant is also used to associated treatment for these conditions: Acromegaly

How Pegvisomant works

Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels.

Food Interaction

No interactions found.

Pegvisomant Drug Interaction

Unknown: charcoal, apomorphine, timolol, sulfamethoxazole / trimethoprim, ubiquinone, entacapone, copper gluconate, glucose, diltiazem, diltiazem, carbidopa / levodopa, sacubitril / valsartan, lamivudine, pirfenidone, anti-inhibitor coagulant complex, antihemophilic factor, givosiran, glycerin, heparin, acetaminophen

Pegvisomant Disease Interaction

Moderate: diabetes, liver dysfunction

Volume of Distribution

• 7 L

Half Life

~6 days

Clearance

• 36 - 28 mL/h [SC doses ranging from 10 to 20 mg/day]

Innovators Monograph

You find simplified version here Pegvisomant